ABOUT THE RESEARCHER

OVERVIEW

The ultimate goals of Joseph Majzoub's work are to understand how various stresses affect health.

The specific aims of the Majzoub laboratory's studies are to analyze beneficial and detrimental effects, and the regulation of, the mammalian stress response, particularly within the brain. Current research focuses on the behavioral and neuroendocrine roles of corticotropin-releasing hormone (CRH), the regulation of CRH gene transcription by silencing factors, and the role of Mrap2 to modulate energy balance during stress, both in the fetus and postnatally.

BACKGROUND

Joseph Majzoub received his MD from Stanford University School of Medicine. He completed an internship and residency in Internal Medicine at Brigham and Women's Hospital and a fellowship in Adult Endocrinology at Massachusetts General Hospital.

He is the recipient of several teaching awards, including the A. Clifford Barger Award for Excellence in Mentoring from Harvard Medical School and the 2002 Irving M. London Teaching Award from Harvard Medical School-Massachusetts Institute of Technology Health Sciences Technology (HST) Program.

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Ultrasonographic Tissue Perfusion in Peri-implant Health and Disease. J Dent Res. 2021 Sep 13; 220345211035684. View abstract
  2. A Resident-Led Virtual Journal Club to Educate Pediatric Residents About Coronavirus Disease 2019. Acad Pediatr. 2021 May-Jun; 21(4):759-761. View abstract
  3. The Changing Face of Adrenoleukodystrophy. Endocr Rev. 2020 08 01; 41(4). View abstract
  4. Correction: The Genomics Research and Innovation Network: creating an interoperable, federated, genomics learning system. Genet Med. 2020 Feb; 22(2):449. View abstract
  5. The Genomics Research and Innovation Network: creating an interoperable, federated, genomics learning system. Genet Med. 2020 02; 22(2):371-380. View abstract
  6. A novel missense mutation in TFAP2B associated with Char syndrome and central diabetes insipidus. . 2019 07; 179(7):1299-1303. View abstract
  7. Glycogen storage disease presenting as Cushing syndrome. JIMD Rep. 2019 May; 47(1):17-22. View abstract
  8. Hyperadrenocorticism of calorie restriction contributes to its anti-inflammatory action in mice. Aging Cell. 2019 06; 18(3):e12944. View abstract
  9. Abnormal Glycerol Metabolism in a Child with Global Developmental Delay, Adrenal Insufficiency, and Intellectual Disability. Clin Chem. 2018 12; 64(12):1785-1787. View abstract
  10. Behavioural dysfunctions of 10-year-old children born extremely preterm associated with corticotropin-releasing hormone expression in the placenta. Acta Paediatr. 2018 11; 107(11):1932-1936. View abstract
  11. A New Model for Adrenarche: Inhibition of 3ß-Hydroxysteroid Dehydrogenase Type 2 by Intra-Adrenal Cortisol. Horm Res Paediatr. 2018; 89(5):311-319. View abstract
  12. Racial differences in neonatal hypoglycemia among very early preterm births. J Perinatol. 2018 03; 38(3):258-263. View abstract
  13. Loss of hypothalamic corticotropin-releasing hormone markedly reduces anxiety behaviors in mice. Mol Psychiatry. 2017 05; 22(5):733-744. View abstract
  14. Maternal first trimester serum levels of free-beta human chorionic gonadotrophin and male genital anomalies. Hum Reprod. 2016 08; 31(8):1895-903. View abstract
  15. Brain disorders associated with corticotropin-releasing hormone expression in the placenta among children born before the 28th week of gestation. Acta Paediatr. 2016 Jan; 105(1):e7-11. View abstract
  16. Endocrinology research-reflecting on the past decade and looking to the next. Nat Rev Endocrinol. 2015 Nov; 11(11):672-80. View abstract
  17. Regulation of human 3ß-hydroxysteroid dehydrogenase type 2 by adrenal corticosteroids and product-feedback by androstenedione in human adrenarche. J Pharmacol Exp Ther. 2015 Jan; 352(1):67-76. View abstract
  18. An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge. Genome Biol. 2014 Mar 25; 15(3):R53. View abstract
  19. Adrenocortical zonation results from lineage conversion of differentiated zona glomerulosa cells. Dev Cell. 2013 Sep 30; 26(6):666-673. View abstract
  20. Loss of function of the melanocortin 2 receptor accessory protein 2 is associated with mammalian obesity. Science. 2013 Jul 19; 341(6143):275-8. View abstract
  21. Epinephrine deficiency results in intact glucose counter-regulation, severe hepatic steatosis and possible defective autophagy in fasting mice. Int J Biochem Cell Biol. 2012 Jun; 44(6):905-13. View abstract
  22. Fetal-placental inflammation, but not adrenal activation, is associated with extreme preterm delivery. Am J Obstet Gynecol. 2012 Mar; 206(3):236.e1-8. View abstract
  23. Cortisol stimulates secretion of dehydroepiandrosterone in human adrenocortical cells through inhibition of 3betaHSD2. J Clin Endocrinol Metab. 2011 Jan; 96(1):E31-9. View abstract
  24. Nocturnal Dexamethasone versus Hydrocortisone for the Treatment of Children with Congenital Adrenal Hyperplasia. Int J Pediatr Endocrinol. 2010; 2010. View abstract
  25. Effect of epinephrine deficiency on cold tolerance and on brown adipose tissue. Mol Cell Endocrinol. 2010 Oct 26; 328(1-2):34-9. View abstract
  26. Monitoring of therapy in congenital adrenal hyperplasia. Clin Chem. 2010 Aug; 56(8):1245-51. View abstract
  27. Glucocorticoid treatment--effect on adrenal medullary catecholamine production. Shock. 2010 Feb; 33(2):213-7. View abstract
  28. Permanent Neonatal Diabetes in a Patient with a KCNJ11/Q52R Mutation Accompanied by Intermittent Hypoglycemia and Liver Failure. Int J Pediatr Endocrinol. 2009; 2009:453240. View abstract
  29. Mass spectrometry in the clinical laboratory: how have we done, and where do we need to be? Clin Chem. 2009 Jun; 55(6):1236-9. View abstract
  30. Maternal levels of corticotropin-releasing hormone during pregnancy in relation to adiponectin and leptin in early childhood. J Clin Endocrinol Metab. 2009 Apr; 94(4):1409-15. View abstract
  31. Long-term effects of dietary glycemic index on adiposity, energy metabolism, and physical activity in mice. Am J Physiol Endocrinol Metab. 2008 Nov; 295(5):E1126-31. View abstract
  32. Genetic diagnosis of primary immune deficiencies. Immunol Allergy Clin North Am. 2008 May; 28(2):387-412, x. View abstract
  33. Elevated midpregnancy corticotropin-releasing hormone is associated with prenatal, but not postpartum, maternal depression. J Clin Endocrinol Metab. 2008 May; 93(5):1946-51. View abstract
  34. Pomc knockout mice have secondary hyperaldosteronism despite an absence of adrenocorticotropin. Endocrinology. 2008 Feb; 149(2):681-6. View abstract
  35. Diabetes insipidus: clinical and basic aspects. Pediatr Endocrinol Rev. 2006 Dec; 4 Suppl 1:60-5. View abstract
  36. Maternal corticotropin-releasing hormone levels during pregnancy and offspring adiposity. Obesity (Silver Spring). 2006 Sep; 14(9):1647-53. View abstract
  37. Measuring corticotropin-releasing hormone in pregnant women - comparing blood collection protocols for epidemiological studies. Paediatr Perinat Epidemiol. 2006 Jan; 20(1):67-71. View abstract
  38. Corticotropin-releasing hormone deficiency increases allergen-induced airway inflammation in a mouse model of asthma. J Allergy Clin Immunol. 2004 Oct; 114(4):747-54. View abstract
  39. Recombinant human growth hormone treatment for dilated cardiomyopathy in children. Pediatrics. 2004 Oct; 114(4):e452-8. View abstract
  40. Perioperative management of diabetes insipidus in children. J Neurosurg Anesthesiol. 2004 Jul; 16(3):220-5. View abstract
  41. Catecholamine synthesizing enzymes and their modulation by immobilization stress in knockout mice. Ann N Y Acad Sci. 2004 Jun; 1018:458-65. View abstract
  42. Urocortin III, a brain neuropeptide of the corticotropin-releasing hormone family: modulation by stress and attenuation of some anxiety-like behaviours. J Neuroendocrinol. 2004 May; 16(5):411-22. View abstract
  43. Maternal activating mutation of the calcium-sensing receptor: implications for calcium metabolism in the neonate. J Pediatr Endocrinol Metab. 2004 Apr; 17(4):673-7. View abstract
  44. Impaired leptin expression and abnormal response to fasting in corticotropin-releasing hormone-deficient mice. Endocrinology. 2004 Jul; 145(7):3174-81. View abstract
  45. Perioperative management of diabetes insipidus in children [corrected]. J Neurosurg Anesthesiol. 2004 Jan; 16(1):14-9. View abstract
  46. Dissecting adrenal and behavioral responses to stress by targeted gene inactivation in mice. Stress. 2003 Jun; 6(2):121-5. View abstract
  47. Lessons from CRH knockout mice. Neuropeptides. 2002 Apr-Jun; 36(2-3):96-102. View abstract
  48. Neural substrates of anorexia nervosa: a behavioral challenge study with positron emission tomography. J Pediatr. 2001 Jul; 139(1):51-7. View abstract
  49. Maternal experiences of racism and violence as predictors of preterm birth: rationale and study design. Paediatr Perinat Epidemiol. 2001 Jul; 15 Suppl 2:124-35. View abstract
  50. The physiology of corticotropin-releasing hormone deficiency in mice. Peptides. 2001 May; 22(5):725-31. View abstract
  51. Repressor element silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) can act as an enhancer as well as a repressor of corticotropin-releasing hormone gene transcription. J Biol Chem. 2001 Apr 27; 276(17):13917-23. View abstract
  52. Exogenous growth hormone: a new therapy for dilated cardiomyopathy. Prog Pediatr Cardiol. 2000 Nov 04; 12(1):125-132. View abstract
  53. Pituitary-adrenal axis regulation in CRH-deficient mice. Endocr Res. 2000 Nov; 26(4):1057-66. View abstract
  54. Asthma, steroids, and growth. N Engl J Med. 2000 Oct 12; 343(15):1113-4. View abstract
  55. Endocrinologic and psychological effects of short-term dexamethasone in anorexia nervosa. Eat Weight Disord. 2000 Sep; 5(3):175-82. View abstract
  56. Effects of various mutations in the neurophysin/glycopeptide portion of the vasopressin gene on vasopressin expression in vitro. Tohoku J Exp Med. 2000 Aug; 191(4):187-202. View abstract
  57. Circadian rise in maternal glucocorticoid prevents pulmonary dysplasia in fetal mice with adrenal insufficiency. Proc Natl Acad Sci U S A. 2000 Jun 20; 97(13):7336-41. View abstract
  58. Corticotropin-releasing hormone links pituitary adrenocorticotropin gene expression and release during adrenal insufficiency. J Clin Invest. 2000 May; 105(9):1269-77. View abstract
  59. Neuroanatomy of human appetitive function: A positron emission tomography investigation. Int J Eat Disord. 2000 Mar; 27(2):163-71. View abstract
  60. Impaired basal and restraint-induced epinephrine secretion in corticotropin-releasing hormone-deficient mice. Endocrinology. 2000 Mar; 141(3):1142-50. View abstract
  61. Impaired Basal and Restraint-Induced Epinephrine Secretion in Corticotropin-Releasing Hormone- Deficient Mice. Endocrinology. 2000 Mar 01; 141(3):1142-1150. View abstract
  62. CRH deficiency impairs but does not block pituitary-adrenal responses to diverse stressors. Neuroendocrinology. 2000 Feb; 71(2):79-87. View abstract
  63. Urocortin expression in the Edinger-Westphal nucleus is up-regulated by stress and corticotropin-releasing hormone deficiency. Endocrinology. 2000 Jan; 141(1):256-63. View abstract
  64. Urocortin Expression in the Edinger-Westphal Nucleus Is Up-Regulated by Stress and Corticotropin-Releasing Hormone Deficiency1. Endocrinology. 2000 Jan 01; 141(1):256-263. View abstract
  65. Corticotropin-releasing hormone stimulates angiogenesis and epithelial tumor growth in the skin. J Invest Dermatol. 1999 Nov; 113(5):838-42. View abstract
  66. Virilising 21-hydroxylase deficiency: timing of newborn screening and confirmatory tests can be crucial. J Pediatr Endocrinol Metab. 1999 Nov-Dec; 12(6):895-901. View abstract
  67. CRH-deficient mice have a normal anorectic response to chronic stress. Regul Pept. 1999 Oct 22; 84(1-3):69-74. View abstract
  68. Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH. Proc Natl Acad Sci U S A. 1999 Jul 06; 96(14):8283-8. View abstract
  69. Pediatric reference intervals for serum thyroxine, triiodothyronine, thyrotropin, and free thyroxine. Clin Chem. 1999 Jul; 45(7):1087-91. View abstract
  70. Corticotropin-releasing hormone deficiency unmasks the proinflammatory effect of epinephrine. Proc Natl Acad Sci U S A. 1999 Jun 08; 96(12):7093-7. View abstract
  71. Inducible binding of cyclic adenosine 3',5'-monophosphate (cAMP)-responsive element binding protein (CREB) to a cAMP-responsive promoter in vivo. Mol Endocrinol. 1999 May; 13(5):659-69. View abstract
  72. Normal suppression of the reproductive axis following stress in corticotropin-releasing hormone-deficient mice. Endocrinology. 1999 Apr; 140(4):1702-8. View abstract
  73. Animal models of CRH deficiency. Front Neuroendocrinol. 1999 Apr; 20(2):122-45. View abstract
  74. High glycemic index foods, overeating, and obesity. Pediatrics. 1999 Mar; 103(3):E26. View abstract
  75. Regulation of hepatic glycogen in the insulin-like growth factor II-deficient mouse. Endocrinology. 1999 Mar; 140(3):1442-8. View abstract
  76. Proliferation and differentiation defects during lung development in corticotropin-releasing hormone-deficient mice. Am J Respir Cell Mol Biol. 1999 Feb; 20(2):181-8. View abstract
  77. Placental corticotropin-releasing hormone: function and regulation. Am J Obstet Gynecol. 1999 Jan; 180(1 Pt 3):S242-6. View abstract
  78. A central theory of preterm and term labor: putative role for corticotropin-releasing hormone. Am J Obstet Gynecol. 1999 Jan; 180(1 Pt 3):S232-41. View abstract
  79. Two novel mutations of the vasopressin gene associated with familial diabetes insipidus and identification of an asymptomatic carrier infant. J Clin Endocrinol Metab. 1998 Nov; 83(11):3958-64. View abstract
  80. Glucocorticoid deficiency delays stratum corneum maturation in the fetal mouse. J Invest Dermatol. 1998 Sep; 111(3):440-4. View abstract
  81. Vasopressin messenger ribonucleic acid regulation via the protein kinase A pathway. Endocrinology. 1998 Jun; 139(6):2831-7. View abstract
  82. Four cases of mucosal neuroma syndrome: multiple endocrine neoplasm 2B or not 2B? J Clin Endocrinol Metab. 1998 Jan; 83(1):17-20. View abstract
  83. Positive and negative regulation of the rat vasopressin gene promoter. Endocrinology. 1997 Dec; 138(12):5266-74. View abstract
  84. Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors. Mol Med. 1997 Dec; 3(12):813-25. View abstract
  85. Sodium balance modulates thirst in normal man. Endocr Res. 1997 Nov; 23(4):377-92. View abstract
  86. Impaired diurnal adrenal rhythmicity restored by constant infusion of corticotropin-releasing hormone in corticotropin-releasing hormone-deficient mice. J Clin Invest. 1997 Jun 15; 99(12):2923-9. View abstract
  87. Protein malnutrition increases plasma adrenocorticotropin and anterior pituitary proopiomelanocortin messenger ribonucleic acid in the rat. Endocrinology. 1997 Mar; 138(3):1048-57. View abstract
  88. CRH and the immune system. J Neuroimmunol. 1997 Feb; 72(2):131-6. View abstract
  89. Chronic central nervous system exposure to interleukin-1 beta causes catabolism in the rat. Am J Physiol. 1996 Nov; 271(5 Pt 2):R1142-8. View abstract
  90. Cortisol blockade of progesterone: a possible molecular mechanism involved in the initiation of human labor. Nat Med. 1996 May; 2(5):556-60. View abstract
  91. Transcription of the human corticotropin-releasing hormone gene in NPLC cells is correlated with Z-DNA formation. Proc Natl Acad Sci U S A. 1996 Apr 16; 93(8):3664-8. View abstract
  92. Knockout mice. N Engl J Med. 1996 Apr 04; 334(14):904-7. View abstract
  93. Production of corticotropin-releasing hormone-deficient mice by targeted mutation in embryonic stem cells. Ann N Y Acad Sci. 1996 Mar 22; 780:49-59. View abstract
  94. Regulation of placental corticotropin-releasing hormone by steroids. Possible implications in labor initiation. Ann N Y Acad Sci. 1995 Dec 29; 771:551-5. View abstract
  95. Molecular and transgenic studies of the corticotropin-releasing hormone gene. Ann N Y Acad Sci. 1995 Dec 29; 771:293-300. View abstract
  96. Corticotropin-releasing hormone deficiency reveals major fetal but not adult glucocorticoid need. Nature. 1995 Feb 02; 373(6513):427-32. View abstract
  97. Expression of the mouse corticotropin-releasing hormone gene in vivo and targeted inactivation in embryonic stem cells. J Clin Invest. 1994 May; 93(5):2066-72. View abstract
  98. Regulation of the ectopically expressed human glycoprotein alpha-subunit gene in the human hepatoma cell line NPLC. Endocrinology. 1994 Feb; 134(2):582-7. View abstract
  99. Corticotrophin releasing hormone levels in human plasma and amniotic fluid during gestation. Clin Endocrinol (Oxf). 1994 Feb; 40(2):257-62. View abstract
  100. Effects of hydroxyurea and cyclic adenosine monophosphate/protein kinase A inhibitors on the expression of the human chorionic gonadotropin alpha subunit and c-myc genes in choriocarcinoma. J Endocrinol Invest. 1993 Dec; 16(11):849-56. View abstract
  101. Contribution of vasopressin to blood pressure regulation during hypovolemic hypotension in humans. J Appl Physiol (1985). 1993 Nov; 75(5):1984-8. View abstract
  102. Transgenic mouse models of vasopressin expression. Hypertension. 1993 Oct; 22(4):640-5. View abstract
  103. Tissue-specific expression and osmotic regulation of a rat vasopressin gene in transgenic mice. Ann N Y Acad Sci. 1993 Jul 22; 689:530-3. View abstract
  104. Expression of the rat arginine vasopressin gene in transgenic mice. Mol Endocrinol. 1993 May; 7(5):659-67. View abstract
  105. Differential regulation of choriocarcinoma gene expression by DNA synthesis inhibitors. Endocr J. 1993 Apr; 40(2):263-8. View abstract
  106. Second messenger regulation of mRNA for corticotropin-releasing factor. Ciba Found Symp. 1993; 172:30-43; discussion 43-58. View abstract
  107. Regulated expression of vasopressin gene by cAMP and phorbol ester in primary rat fetal hypothalamic cultures. Mol Cell Endocrinol. 1992 Jul; 86(1-2):29-36. View abstract
  108. Effects of glucocorticoid on corticotropin-releasing hormone gene regulation by second messenger pathways in NPLC and AtT-20 cells. Endocrinology. 1992 Apr; 130(4):2237-44. View abstract
  109. Protein kinase-C activation increases the quantity and poly(A) tail length of corticotropin-releasing hormone messenger RNA in NPLC cells. Mol Endocrinol. 1992 Mar; 6(3):476-84. View abstract
  110. The effect of insulin-induced hypoglycemia on gene expression in the hypothalamic-pituitary-adrenal axis of the rat. Endocrinology. 1992 Feb; 130(2):920-5. View abstract
  111. Regulation of gene expression in choriocarcinoma by methotrexate and hydroxyurea. Endocrinology. 1991 Feb; 128(2):972-8. View abstract
  112. Both cyclooxygenase-dependent and cyclooxygenase-independent pathways mediate the neuroendocrine response in humans. Surgery. 1990 Aug; 108(2):254-9; discussion 259-61. View abstract
  113. Second messengers involved in the regulation of corticotropin-releasing hormone mRNA and peptide in cultured rat fetal hypothalamic primary cultures. Endocrinology. 1990 Jun; 126(6):3016-21. View abstract
  114. Regulated expression of the human corticotropin releasing hormone gene by cyclic AMP. Mol Cell Endocrinol. 1990 Apr 17; 70(2):165-74. View abstract
  115. Differential regulation of corticotropin-releasing hormone mRNA in rat brain. Am J Physiol. 1990 Apr; 258(4 Pt 1):E686-92. View abstract
  116. The testicular effects of tumor necrosis factor. Ann Surg. 1990 Apr; 211(4):470-5. View abstract
  117. Developmental expression of corticotropin releasing hormone messenger RNA and peptide in rat hypothalamus. Peptides. 1989 Nov-Dec; 10(6):1165-9. View abstract
  118. Vasopressin-mediated forearm vasodilation in normal humans. Evidence for a vascular vasopressin V2 receptor. J Clin Invest. 1989 Aug; 84(2):418-26. View abstract
  119. Increases in plasma digitalis-like factor activity during insulin-induced hypoglycemia. Neuroendocrinology. 1989 Jun; 49(6):586-91. View abstract
  120. Species-specific placental corticotropin releasing hormone messenger RNA and peptide expression. Mol Cell Endocrinol. 1989 Apr; 62(2):337-41. View abstract
  121. Preprocorticotropin releasing hormone: cDNA sequence and in vitro processing. Mol Cell Endocrinol. 1989 Feb; 61(2):175-80. View abstract
  122. Vasopressin mRNA in the suprachiasmatic nuclei: daily regulation of polyadenylate tail length. Science. 1988 Jul 15; 241(4863):342-4. View abstract
  123. Glucocorticoid stimulates expression of corticotropin-releasing hormone gene in human placenta. Proc Natl Acad Sci U S A. 1988 Jul; 85(14):5244-8. View abstract
  124. Characterization and gestational regulation of corticotropin-releasing hormone messenger RNA in human placenta. J Clin Invest. 1988 Jul; 82(1):287-92. View abstract
  125. The vasopressin mRNA poly(A) tract is unusually long and increases during stimulation of vasopressin gene expression in vivo. Mol Cell Biol. 1988 Jun; 8(6):2267-74. View abstract
  126. A chemically synthesized radiolabeled signal peptide: design, preparation, and biological evaluation of an iodinated analog of preproparathyroid hormone. Mol Endocrinol. 1988 May; 2(5):452-8. View abstract
  127. Expression and dexamethasone regulation of the human corticotropin-releasing hormone gene in a mouse anterior pituitary cell line. J Biol Chem. 1988 Apr 25; 263(12):5846-52. View abstract
  128. Human corticotropin releasing hormone gene is located on the long arm of chromosome 8. Cytogenet Cell Genet. 1988; 47(3):113-6. View abstract
  129. Relationship of cardiac chamber volume to baroreflex activity in normal humans. J Clin Endocrinol Metab. 1987 Sep; 65(3):475-81. View abstract
  130. Influence of infused hypertonic saline on the response to insulin-induced hypoglycemia in man. J Clin Endocrinol Metab. 1987 Jul; 65(1):116-21. View abstract
  131. Defective regulation of vasopressin gene expression in Brattleboro rats. Am J Physiol. 1987 May; 252(5 Pt 1):E637-42. View abstract
  132. Vasopressin gene is expressed at low levels in the hypothalamus of the Brattleboro rat. Proc Natl Acad Sci U S A. 1984 Sep; 81(17):5296-9. View abstract
  133. Vasopressin and oxytocin mRNA regulation in the rat assessed by hybridization with synthetic oligonucleotides. J Biol Chem. 1983 Dec 10; 258(23):14061-4. View abstract
  134. Cellular and cell-free processing of parathyroid secretory proteins. J Biol Chem. 1982 Apr 10; 257(7):3581-8. View abstract
  135. Synthetic pre-proparathyroid hormone leader sequence inhibits cell-free processing of placental, parathyroid, and pituitary prehormones. J Biol Chem. 1980 Dec 10; 255(23):11478-83. View abstract
  136. Cloning and nucleotide sequence of DNA coding for bovine preproparathyroid hormone. Proc Natl Acad Sci U S A. 1979 Oct; 76(10):4981-5. View abstract
  137. Identification and cell-free translation of mRNA coding for a precursor of parathyroid secretory protein. J Biol Chem. 1979 Aug 10; 254(15):7449-55. View abstract
  138. Letter: "Smudge" ECG. N Engl J Med. 1975 Jan 02; 292(1):50. View abstract